SVRA - Savara Inc
IEX Last Trade
4.28
0.060 1.402%
Share volume: 1,079,293
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$4.22
0.06
1.42%
Fundamental analysis
10%
Profitability
0%
Dept financing
7%
Liquidity
50%
Performance
10%
Performance
5 Days
-2.29%
1 Month
0.23%
3 Months
3.89%
6 Months
-16.11%
1 Year
13.87%
2 Year
205.00%
Key data
Stock price
$4.28
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.12 - $5.70
52 WEEK CHANGE
$0.11
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Robert Neville
Region: US
Website: http://savarapharma.com/
Employees: 42
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://savarapharma.com/
Employees: 42
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Recent news